Holen Sie sich die Stockscreener-App
20.73
2.26%
0.395
Schlusskurs vom Vortag:
$20.34
Offen:
$20.74
24-Stunden-Volumen:
27,643
Relative Volume:
0.09
Marktkapitalisierung:
$1.15B
Einnahmen:
$29.71M
Nettoeinkommen (Verlust:
$-69.15M
KGV:
-40.42
EPS:
-0.513
Netto-Cashflow:
$-52.28M
1W Leistung:
+12.43%
1M Leistung:
-2.16%
6M Leistung:
+55,814%
1J Leistung:
+55,814%
1-Tages-Spanne:
$20.64
$21.20
1-Wochen-Bereich:
$18.36
$21.20
52-Wochen-Spanne:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Firmenname
Aktis Oncology Inc
Sektor
Branche
Telefon
978-237-4380
Adresse
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
20.73 | 1.12B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
435.53 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.51 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
801.54 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.67 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | BofA Securities | Buy |
| 2026-02-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-02-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-03 | Eingeleitet | TD Cowen | Buy |
| 2024-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-02 | Bestätigt | Craig Hallum | Buy |
| 2021-01-15 | Bestätigt | Craig Hallum | Buy |
| 2019-09-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2018-11-30 | Eingeleitet | Lake Street | Buy |
| 2018-06-22 | Eingeleitet | Loop Capital | Buy |
| 2018-02-09 | Eingeleitet | Drexel Hamilton | Buy |
Alle ansehen
Aktis Oncology Inc Aktie (AKTS) Neueste Nachrichten
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
Aktis: Q1 Earnings Snapshot - 10TV
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times
Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView
Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan
Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo
Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan
Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com Australia
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
Aktis Oncology starts Phase 1b trial of AKY-2519 for advanced prostate cancer targeting B7-H3 tumors - Pluang
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Sahm
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $32 - Moomoo
William Blair Initiates Aktis Oncology at Outperform - Moomoo
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS) - Seeking Alpha
Massachusetts biotech IPOs surge after years of drought - The Business Journals
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance
Aktis Oncology prices IPO at $18 per share - MSN
Economics Weekly: Capacity Growth—It’s Different This Time - William Blair
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Intuitive Surgical (ISRG) - The Globe and Mail
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Aktis Oncology to Present Clinical Data on AKY-2519 Targeting B7-H3 at 2026 ASCO Annual Meeting - Quiver Quantitative
Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan
Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Yahoo Finance
Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com - Investing.com India
Should I buy Aktis Oncology, Inc. (AKTS) - Zacks Investment Research
Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options - Stock Titan
Finanzdaten der Aktis Oncology Inc-Aktie (AKTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aktis Oncology Inc-Aktie (AKTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):